Trial site
Advanced Urology Institute
Daytona Beach, Florida 32114, United StatesNot linked to an institution yet
- 7running trials
- 2closed trials
The trials here
What the 9 trials at this site are about, from their registry records.
- Phase
- Phase 35 trials
- Phase 1/21 trial
- Phase 21 trial
- Status
- Active, not recruiting5 trials
- Completed2 trials
- Recruiting2 trials
- Lead sponsor
- Janssen Research & Development, LLC3 trials
- Sumitomo Pharma America, Inc.2 trials
- Bayer1 trial
- CG Oncology, Inc.1 trial
- Dendreon1 trial
- and 1 more
Running trials
Active, not recruiting
A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT
NCT06111235· Phase 3· CG Oncology, Inc.· Source
Recruiting
Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T
NCT06134232· Phase 2· Dendreon· Source
Contact: Evan Fynes, MD
Active, not recruiting
A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC
NCT05884398· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
A Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer
NCT05710848· Phase 1/2· SURGE Therapeutics· Source
Contact: Sara Esposito
Active, not recruiting
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-MutatedProstatic Neoplasms (mCSPC)
NCT04497844· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
A Study in Which Non-metastatic Castration-resistant Prostate Cancer (nmCRPC) Patients for Whom a Decision to Treat With Darolutamide Has Been Made Before Enrollment Are Observed and Certain Outcomes Are Described
NCT04122976· Bayer· Source
Active, not recruiting
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer
NCT03748641· Phase 3· Janssen Research & Development, LLC· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error